Global Chilblains Treatment Market, By Symptom (Itching, Pain, Inflammation), Gender (Male, Female), Population at Risk (Smokers, Diabetic Patients, Patients Having Low BMI, Patients Suffering From Systemic Lupus Erythematosus, Others), Site (Fingers, Toes, Ear Lobes, Nose, Cheeks, Heels), Drug Type (Branded, Generic), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Chilblains Treatment Market Analysis and Size
Chilblains usually develop after a long exposure to the cold. They typically cause a burning and itching sensation in the much affected areas, that can become more intense if one gets into a warm room. Some people develop chilblains that last for few months every winter. Chilblains often get better after a week or two even without the treatment. Suppose people suffer from severe or recurring chilblains. In that case, there's a slighest risk of further problems developing, such as infection from blistered or scratched skin, permanent discoloration of the skin, ulcers forming on the skin, and scarring of the skin.
Data Bridge Market Research analyses a growth rate in the chilblains treatment market in the forecast period 2023-2030. The expected CAGR of the chilblains treatment market is around 3.90% in the forecast period. The market was valued at USD 500 million in 2022, and it would grow to USD 679.04 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chilblains Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Symptom (Itching, Pain, Inflammation), Gender (Male, Female), Population at Risk (Smokers, Diabetic Patients, Patients Having Low BMI, Patients Suffering From Systemic Lupus Erythematosus, Others), Site (Fingers, Toes, Ear Lobes, Nose, Cheeks, Heels), Drug Type (Branded, Generic), Route of Administration (Oral, Topical, Others),End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc. (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Zydus Group (India), Lupin (India), Bayer AG (Germany), Invisionmedi (India), Unichem Laboratories (India), Torrent Pharmaceuticals Ltd (India), Cadila Pharmaceuticals (India), Piramal Enterprises Ltd. (India), Lupin (India), Lannett (U.S.), Viatris Inc.(U.S.), Par Pharmaceutical. (U.S.), Grevis Pharmaceuticals Pvt. Ltd (India), Osmotica Pharmaceuticals (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Chilblains are itchy, small red coloured swellings on skin, usually caused by abnormal skin reactions to cold occurring on extremities, that tend to get cold easily. Chilblains, also called pernio, are painful because of inflammation of small blood vessels in skin. Chilblains can occur in any age, but are most prevalent in children and older people, chilblains are more frequent in females. Currently, the exact reason for the occurrence of chilblains is unknown, which is a challenge for the associated market.
Chilblains Treatment Market Dynamics
Drivers
- Rise in Skin Infections
The incidence of skin infections has been witnessed worldwide, such as pyoderma (prevalence range 0.2-35%, tinea capitis 1-19.7%, scabies 0.2-24%, viral skin disorders 0.4-9%, mostly molluscum contagiosum, pediculosis capitis 0-57%). This boosts the growth of the market.
- Increase in Smoking
Cigarette smoking is one of the leading causes of preventable disease and death in the U.S. It accounts for more than 480,000 deaths every year. Nicotine causes the blood vessels to constrict, which can make chilblains worse. Thus, smoking exaggerates the clinical symptoms and demands urgency of treatment. Thus, it helps in the market growth.
Opportunities
- Increasing Diabetes Cases
The number of people with diabetes increased from 108 million in 1980 to 422 million in 2014. Incidence has risen more rapidly in low and middle-income countries than in high-income countries. In 2019, diabetes and kidney disease because of diabetes caused an estimated 2 million deaths. An increase in diabetic population will increase the market, as diabetic population is more susceptible to chilblains.
- Increasing Demand for Retail Pharmacies
The rise in the number of chilblains therapeutics delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for market growth. Furthermore, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Limited Studies and Surveys
There are very limited studies and surveys that are impeding the growth of the market. Only a small amount of data are accessible concerning the clinical and research studies. A few studies mainly focused on groups from a single hospital where only a limited number of patients were observed. Thus, this impedes the growth of the market.
- High Cost
The huge expenditure associated with chilblains medications hampers the market growth. This disease involves treatment with corticosteroids, and different immunosuppressive agents, which demands huge expenditure. This acts as a major limitation for the market.
This chilblains treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chilblains treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Chilblains Treatment Market Scope
The chilblains treatment market is segmented on the basis of symptom, gender, population at risk, site, drug type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Symptom
- Itching
- Pain
- Inflammation
Gender
- Male
- Female
Population at Risk
- Smokers
- Diabetic Patients
- Patients Having Low BMI
- Patients Suffering From Systemic Lupus Erythematosus
- Others
Site
- Fingers
- Toes
- Ear Lobes
- Nose
- Cheeks
- Heels
Drug Type
- Branded
- Generic
Route of Administration
- Oral
- Topical
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Chilblains Treatment Market Regional Analysis/Insights
The chilblains treatment market is analyzed and market size insights and trends are provided by symptom, gender, population at risk, site, drug type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the chilblains treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for the chilblains treatment market throughout the forecasted period due to the high healthcare expenditure, good quality medical facilities, and awareness regarding chilblains.
Asia-Pacific dominates the market due to increased new research and developments on skin infections medications and the growth and expansion of healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Chilblains Treatment Market Share Analysis
The chilblains treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chilblains treatment market
Key players operating in the chilblains treatment market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Bayer AG (Germany)
- Invisionmedi (India)
- Unichem Laboratories (India)
- Torrent Pharmaceuticals Ltd (India)
- Cadila Pharmaceuticals (India)
- Piramal Enterprises Ltd. (India)
- Lupin (India)
- Lannett (U.S.)
- Viatris Inc.(U.S.)
- Par Pharmaceutical. (U.S.).
- Grevis Pharmaceuticals Pvt. Ltd (India)
- Osmotica Pharmaceuticals (U.S.)
SKU-